Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression

Drug-resistant mental disorders, particularly treatment-resistant depression, pose a significant medical and social problem. To address this challenge, modern psychiatry is constantly exploring the use of novel treatment methods, including biological treatments, such as transcranial magnetic stimulation (TMS), and novel rapid-acting antidepressants, such as ketamine. While both TMS and ketamine demonstrate high effectiveness in reducing the severity of depressive symptoms, some patients still do not achieve the desired improvement. Recent literature suggests that combining these two methods may yield even stronger and longer-lasting results. This review aims to consolidate knowledge in this area and elucidate the potential mechanisms of action underlying the increased efficacy of combined treatment, which would provide a foundation for the development and optimization of future treatment protocols.

[1]  Marcel Green,et al.  Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery , 2023, Cureus.

[2]  P. Lespérance,et al.  Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. , 2023, Journal of affective disorders.

[3]  R. Schoevers,et al.  Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. , 2022, The lancet. Psychiatry.

[4]  P. Lespérance,et al.  Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report , 2022, Frontiers in Psychiatry.

[5]  Zhenyu Hu,et al.  The molecular pathophysiology of depression and the new therapeutics , 2022, MedComm.

[6]  R. Cui,et al.  Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant , 2022, Frontiers in Pharmacology.

[7]  Renhong He,et al.  Repetitive transcranial magnetic stimulation promotes neurological functional recovery in rats with traumatic brain injury by upregulating synaptic plasticity-related proteins , 2022, Neural regeneration research.

[8]  SJ McPherson,et al.  Psychological treatments for persistent depression: A systematic review and meta-analysis of quality of life and functioning outcomes. , 2022, Psychotherapy.

[9]  Supplemental Material for Psychological Treatments for Persistent Depression: A Systematic Review and Meta-Analysis of Quality of Life and Functioning Outcomes , 2022, Psychotherapy.

[10]  J. González-Olvera,et al.  5 Hz of repetitive transcranial magnetic stimulation improves cognition and induces modifications in hippocampal neurogenesis in adult female Swiss Webster mice , 2022, Brain Research Bulletin.

[11]  Nelson B Rodrigues,et al.  Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. , 2022, Journal of psychiatric research.

[12]  Jianguo Chen,et al.  Repetitive transcranial magnetic stimulation exerts anti-inflammatory effects via modulating glial activation in mice with chronic unpredictable mild stress-induced depression. , 2022, International immunopharmacology.

[13]  G. Kranz,et al.  The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach , 2022, Frontiers in Molecular Neuroscience.

[14]  J. Port,et al.  Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation , 2022, The international journal of neuropsychopharmacology.

[15]  D. Pavel,et al.  Brain SPECT as an Imaging Biomarker for Evaluating Effects of Novel Treatments in Psychiatry–A Case Series , 2022, Frontiers in Psychiatry.

[16]  A. Sack,et al.  A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression , 2022, Frontiers in Psychiatry.

[17]  M. Shigeta,et al.  Transcranial magnetic stimulation modalities for psychiatric disorders: Publication trends from 1985 to 2019 , 2021, Neuropsychopharmacology reports.

[18]  F. Ye,et al.  Author Correction: Structural basis of ketamine action on human NMDA receptors , 2021, Nature.

[19]  K. Kuypers,et al.  Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics , 2021, Frontiers in Psychiatry.

[20]  F. Ye,et al.  Structural basis of ketamine action on human NMDA receptors , 2021, Nature.

[21]  Á. Pascual-Leone,et al.  Day-to-day variability in motor threshold during rTMS treatment for depression: Clinical implications , 2021, Brain Stimulation.

[22]  A. Young,et al.  Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. , 2021, The American journal of psychiatry.

[23]  Oscar G. Morales,et al.  Borderline personality traits do not influence response to TMS. , 2020, Journal of affective disorders.

[24]  S. Rossi,et al.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines , 2020, Clinical Neurophysiology.

[25]  M. Cacic,et al.  Therapeutic Mechanisms of Ketamine. , 2020, Psychiatria Danubina.

[26]  C. Zarate,et al.  Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. , 2020, Journal of affective disorders.

[27]  W. Marcantoni,et al.  A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. , 2020, Journal of affective disorders.

[28]  S. Dursun,et al.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers , 2020, Therapeutic Advances in Psychopharmacology.

[29]  Sa-Ik Hong,et al.  Rodent models for psychiatric disorders: problems and promises , 2020, Laboratory Animal Research.

[30]  K. Sudheimer,et al.  Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. , 2020, The American journal of psychiatry.

[31]  S. Rossi,et al.  Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018) , 2019, Clinical Neurophysiology.

[32]  R. Duman,et al.  Neuroplasticity in cognitive and psychological mechanisms of depression: An integrative model , 2019, Molecular Psychiatry.

[33]  K. Hashimoto,et al.  Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites , 2019, Translational Psychiatry.

[34]  D. Pavel,et al.  Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use , 2019, Heliyon.

[35]  R. Cho,et al.  Neurophysiological Effect of Ketamine on Prefrontal Cortex in Treatment-Resistant Depression: A Combined Transcranial Magnetic Stimulation–Electroencephalography Study , 2019, Chronic stress.

[36]  T. Blackburn Depressive disorders: Treatment failures and poor prognosis over the last 50 years , 2019, Pharmacology research & perspectives.

[37]  Jennifer W. Evans,et al.  Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration , 2018, Biological Psychiatry.

[38]  D. S. del Ángel,et al.  Neuroprogression: the hidden mechanism of depression , 2018, Neuropsychiatric disease and treatment.

[39]  Teddy J. Akiki,et al.  Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients , 2018, Chronic stress.

[40]  S. Dursun,et al.  Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness , 2018, Journal of psychopharmacology.

[41]  J. Ramos-Quiroga,et al.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review , 2018, CNS Drugs.

[42]  Jonathan Downar,et al.  Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial , 2018, The Lancet.

[43]  T. Gould,et al.  Mechanisms of ketamine action as an antidepressant , 2018, Molecular Psychiatry.

[44]  S. Thompson,et al.  Convergent Mechanisms Underlying Rapid Antidepressant Action , 2018, CNS Drugs.

[45]  M. Milak,et al.  Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. , 2017, The American journal of psychiatry.

[46]  E. Ballard,et al.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.

[47]  A. Phillips,et al.  Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism , 2017, Journal of psychiatry & neuroscience : JPN.

[48]  J. Sato,et al.  The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder , 2017, Neuropsychopharmacology.

[49]  Elisabeth Bernhardt,et al.  Using neuroimaging to individualize TMS treatment for depression: Toward a new paradigm for imaging-guided intervention , 2017, NeuroImage.

[50]  G. Thickbroom,et al.  Repetitive Transcranial Magnetic Stimulation of the Brain , 2017, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[51]  T. Han,et al.  Repetitive Transcranial Magnetic Stimulation to the Unilateral Hemisphere of Rat Brain. , 2016, Journal of visualized experiments : JoVE.

[52]  E. Seifritz,et al.  Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network. , 2016, Social cognitive and affective neuroscience.

[53]  K. Hagi,et al.  Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories , 2016, Psychological Medicine.

[54]  M. Frye,et al.  Transcranial magnetic stimulation potentiates glutamatergic neurotransmission in depressed adolescents , 2016, Psychiatry Research: Neuroimaging.

[55]  T. Svensson,et al.  Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat , 2015, European Neuropsychopharmacology.

[56]  C. Duarte,et al.  Regulation of hippocampal synaptic plasticity by BDNF , 2015, Brain Research.

[57]  M. Piradov,et al.  Possible Mechanisms Underlying the Therapeutic Effects of Transcranial Magnetic Stimulation , 2015, Front. Hum. Neurosci..

[58]  S. Best Combined ketamine and transcranial magnetic stimulation for treatment resistant depression in the context of chronic OCD: a case report , 2015 .

[59]  K. Laws,et al.  The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.

[60]  D. Pavel,et al.  Ketamine and transcranial magnetic stimulation treatment for bipolar II disorder: a case report , 2015, Journal of Medical Case Reports.

[61]  P. Blier,et al.  Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons , 2015, Journal of psychopharmacology.

[62]  S. Best,et al.  Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report , 2015, The International journal of neuroscience.

[63]  S. Best Combined ketamine/transcranial magnetic stimulation treatment of severe depression in bipolar I disorder. , 2014, The journal of ECT.

[64]  Zhi-qiang Zhou,et al.  Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex , 2014, European Psychiatry.

[65]  R. Steven,et al.  Rapid Relief of Treatment Resistant Depression by Facilitated Ketamine Infusion: A Preliminary Report , 2014 .

[66]  M. Merzenich,et al.  Brain plasticity-based therapeutics , 2014, Front. Hum. Neurosci..

[67]  C. Pittenger Disorders of memory and plasticity in psychiatric disease , 2013, Dialogues in clinical neuroscience.

[68]  D. Charney,et al.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.

[69]  Zhi-qiang Zhou,et al.  Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test , 2013, Upsala journal of medical sciences.

[70]  P. Schwenkreis,et al.  Influence of (S)-ketamine on human motor cortex excitability , 2012, Experimental Brain Research.

[71]  S. Kito,et al.  Cerebral blood flow ratio of the dorsolateral prefrontal cortex to the ventromedial prefrontal cortex as a potential predictor of treatment response to transcranial magnetic stimulation in depression , 2012, Brain Stimulation.

[72]  H. Solvason,et al.  TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICE , 2012, Depression and anxiety.

[73]  David L. Hunt,et al.  Synaptic plasticity of NMDA receptors: mechanisms and functional implications , 2012, Current Opinion in Neurobiology.

[74]  C. Belzung,et al.  Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression , 2011, Biology of Mood & Anxiety Disorders.

[75]  Abraham Zangen,et al.  Long-Term Effects of Repetitive Transcranial Magnetic Stimulation on Markers for Neuroplasticity: Differential Outcomes in Anesthetized and Awake Animals , 2011, The Journal of Neuroscience.

[76]  Á. Pascual-Leone,et al.  The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression. , 2010, Journal of visualized experiments : JoVE.

[77]  Sarah H. Lisanby,et al.  Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study , 2010, Brain Stimulation.

[78]  D. Charney,et al.  Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.

[79]  S. Rossi,et al.  Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research , 2009, Clinical Neurophysiology.

[80]  Yogesh K. Dwivedi Brain-derived neurotrophic factor: role in depression and suicide , 2009, Neuropsychiatric disease and treatment.

[81]  H. Möller,et al.  Acute prefrontal rTMS increases striatal dopamine to a similar degree as d-amphetamine , 2007, Psychiatry Research: Neuroimaging.

[82]  William W. McDonald,et al.  Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial , 2007, Biological Psychiatry.

[83]  P. Schlattmann,et al.  Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. , 2007, Journal of psychiatric research.

[84]  Sarah H Lisanby,et al.  Antidepressant-Induced Neurogenesis in the Hippocampus of Adult Nonhuman Primates , 2007, The Journal of Neuroscience.

[85]  J. Rothwell,et al.  The after-effect of human theta burst stimulation is NMDA receptor dependent , 2007, Clinical Neurophysiology.

[86]  P. Fitzgerald,et al.  A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition , 2006, Clinical Neurophysiology.

[87]  E. Schuman,et al.  Dendritic Protein Synthesis, Synaptic Plasticity, and Memory , 2006, Cell.

[88]  T. Bliss,et al.  Plasticity in the human central nervous system. , 2006, Brain : a journal of neurology.

[89]  R. Yoshimura,et al.  High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. , 2006, Pharmacopsychiatry.

[90]  P. Pasqualetti,et al.  Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation , 2003, The Journal of physiology.

[91]  W. Drevets Neuroimaging studies of mood disorders , 2000, Biological Psychiatry.

[92]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[93]  A P Rudell,et al.  Transcranial magnetic stimulation in study of the visual pathway. , 1998, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[94]  T. Zyss,et al.  Preliminary comparison of behavioral and biochemical effects of chronic transcranial magnetic stimulation and electroconvulsive shock in the rat , 1997, Biological Psychiatry.

[95]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[96]  R. Belmaker,et al.  The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression , 1995, Brain Research.

[97]  Mark Hallett,et al.  Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression , 1995, Neuroreport.

[98]  M. Bear,et al.  Synaptic plasticity: LTP and LTD , 1994, Current Opinion in Neurobiology.

[99]  M. Merzenich,et al.  Cortical plasticity and memory , 1993, Current Opinion in Neurobiology.

[100]  Karl J. Friston,et al.  The anatomy of melancholia – focal abnormalities of cerebral blood flow in major depression , 1992, Psychological Medicine.

[101]  J. Mazziotta,et al.  Reduction of prefrontal cortex glucose metabolism common to three types of depression. , 1989, Archives of general psychiatry.

[102]  A. Barker,et al.  NON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX , 1985, The Lancet.

[103]  A. Coppen The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.

[104]  W. H. Ganti Conditioned Reflexes and Neuron Organization , 1950 .

[105]  A. Nierenberg,et al.  Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions , 2023, World psychiatry : official journal of the World Psychiatric Association.

[106]  Jennifer W. Evans,et al.  Functional MRI markers for treatment-resistant depression: Insights and challenges. , 2023, Progress in brain research.

[107]  steveBesta,et al.  Combined transcranial Magnetic stimulation and Ketamine for treatment of suicidal ideation , Refractory Mood Disorder , neurotoxicity and pain : a Case Report , 2017 .

[108]  B. Bradley,et al.  ACNP 56th Annual Meeting: Poster Session I, December 4, 2017 , 2017, Neuropsychopharmacology.

[109]  D. Pavel,et al.  Combined transcranial magnetic stimulation and ketamine for treatment of refractory mood disorder , anxiety , and pain : A case report , 2017 .

[110]  J. C. Rothwell,et al.  Magnetic stimulation : motor evoked potentials , 2010 .

[111]  行正 徹 High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors , 2007 .

[112]  P. Rossini,et al.  Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. , 1999, Electroencephalography and clinical neurophysiology. Supplement.